Stocktoria
QIAGEN N.V. QGEN
QIAGEN N.V. (QGEN) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.67% (safety: safe). FY2025 revenue was $2.1B at a 20.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.59 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-23 | Morgan Stanley | Overweight (up) |
| 2026-05-18 | Stifel | Hold (main) |
| 2026-05-07 | TD Cowen | Hold (main) |
| 2026-04-29 | JP Morgan | Overweight (main) |
| 2026-04-29 | Citigroup | Neutral (main) |
| 2026-04-29 | Barclays | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.236 |
| Retained earnings / assets | 0.438 |
| EBIT / assets | 0.074 |
| Equity / liabilities | 1.509 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| TECH | BIO-TECHNE Corp | 5/9 | 5.89 | 151.4 | +5.2% |
| NVAX | NOVAVAX INC | 4/9 | -7.28 | 3.3 | +64.7% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
About QIAGEN N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
FAQ
Is QGEN financially healthy?
QIAGEN N.V.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does QGEN pay a dividend, and is it safe?
Yes. QIAGEN N.V. pays a dividend yielding about 0.67% with a 12.8% payout ratio, rated “safe” for safety.
How profitable is QGEN?
In FY2025, QIAGEN N.V. had a net margin of 20.3% and a return on equity of 11.2%.
Is QGEN overvalued or undervalued?
QIAGEN N.V. trades at about 22.2× trailing earnings — below its 10-year norm (10-year range 23.1×–203.3×, median 44.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for QGEN?
The average Wall-Street price target for QIAGEN N.V. is $43.96, about 2.2% above the recent price, from 14 analysts (consensus: buy).
Is QGEN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on QIAGEN N.V.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 19.1×, a dividend yield of 0.67%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.